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Why Study Tobacco Use?
•Tobacco use is the leading cause of PREVENTABLE 
death in the U.S.
•Each day > 4,000 youth ages 12-17 start smoking 
cigarettes
•Each year >400,000 Americans die from tobacco 
smoking
•High comorbidity with alcohol and drug 
dependence
Source: 2006-7 AMA-RFS Public Health Committee
• 1 in 5 Americans is tobacco dependent.
• Current FDA-approved medications are 
successful for only 1 in 3 smokers.
Our Challenge
An Investment in Nicotine Dependence 
Medication Development
Academic scientists can (and should) 
contribute to the development of safe and 
effective medications for nicotine 
dependence
Lerman et al. Nature Reviews Drug Discovery, 2007
Tobacco Use Research Center P50 (1999- )
Scientific Mission
To translate discoveries in 
neuroscience, pharmacology, and 
genetics to improve treatment for 
nicotine dependence
Translational Research Examples
Laboratory to the clinic and back
• Opioid genetic mechanisms in nicotine   
reward and relapse
• COMT as a novel therapeutic target for 
nicotine dependence
Laboratory to the clinic to the community
• Nicotine metabolite ratio as a biomarker of 























Drug Development for Tobacco Dependence
Opioid genetic mechanisms in 
nicotine reward and relapse
Exon1*
Opioid Mechanisms in Nicotine Reward
Eric Nestler
Mouse Model of  Nicotine Reward
Preconditioning Day
Test Day
A                B
A                B
A                B












Work by Julie Blendy
Naloxone on Test Day Blocks Conditioned Rewarding 













































Walters et al, Neuron, 2005
Nicotine 
(2.0mg/kg)
Nicotine on Pairing Days
The Human OPRM1 Gene
PROMOTOR       EXON 1    EXON 2   EXON 3        EXON 4  3’UTR
A118G
•The human OPRM1 gene includes a common Exon 1 Asn40Asp 
(A118G) mis-sense single nucleotide polymorphism (SNP).  
•G allele associated with reduced mRNA expression and protein 
levels (Zhang et al)
•Present in 25-30% of persons of European ancestry 
Hypothesis: Smokers with G allele will have a lower liability to 
relapse in smoking cessation treatment 
Open Label Pharmacogenetic Trial of 
NRT (n=600*)
Nicotine nasal 
spray x 8 wks
Transdermal 
nicotine x 8 wks
Follow-Up: EOT, 6-months, and 12-months




*European ancestry only (n=420)
OR= 1.9,  p=.01
OPRM1 Asn40Asp Variant is Associated with 


















All Patch Spray All Patch Spray
AA n=238
GA GG n=82
Treatment Phase Follow-up Phase
% quit




Smokers with Asp40 Variant Report Greater 















p=<.001 in linear regression 
model
Lerman et al., Pharmacogenomics J, 2004
Independent Validation in Nicotine Patch Trial    (21mg 
x 8 weeks; n=351)
Asn40/Asn40
HR=0.74  [.55-.98] p=.039 
Asp40/*
1. Do carriers of the OPRM1 G allele (loss of 
function) exhibit reduced nicotine 
reinforcement?
2.    Does naltrexone reduce nicotine 
reinforcement—particularly in smokers 
with OPRM1 G allele?
3. Are females more sensitive to opioid system 
effects on nicotine reward?
What is the Mechanism of Enhanced Therapeutic 









Study Phase 1 Study Phase 2















*NTX or PLACEBO *NTX or PLACEBO
Nicotine choice paradigm Nicotine choice paradigm
N=30 Asn40/Asn40
N=30 Asp40/*
Human Model of Nicotine Reward
• 2 hour deprivation period (to standardize 
exposure without inducing serious 
withdrawal symptoms)
• Initial (blinded) exposure to 4 puffs of Quest 
cigarettes: denic. (.05 mg) vs nic. (.6 mg) 
• Assess subjective effects
• Self-administer 4 puffs from either cigarette 
at 30 minute intervals in 6 trials over a 3-
hour period 
• Outcome measure is number of nicotine 
puffs chosen out of 24 = relative reinforcing 
value of nicotine
Reduced Activity OPRM1 Allele is 























Ray et al. Psychopharmacology, 2006
OPRM1 Genotype Predicts Nicotine 













number of nicotine puffs in 24 (across treatments)
24
P (genotype by gender interaction)=.036
75% of Puffs from Nicotine
50%
Ray et al. Psychopharmacology, 2006
Naltrexone Does Not Reduce Nicotine 













number of nicotine puffs in 24
24
Ray et al. Psychopharmacology, 2006
Using Targeted Genetic Mutations in the Mouse 
to Understand Human OPRM1 SNP (Blendy)
Molecular Cellular Imaging Behavioral
Exon1*
2x2 Factorial Design: (1) 
nicotine vs. denic cig (within 
subject); (2) OPRM1 
genotype (stratified by sex)
Examine MOR Binding as Mechanism for Observed  







rVST lVST rNAC lNAC rTHAL lTHAL rACC lACC OCC
pla
nic
VST=ventral striatum; NAC-nucleus accumbens; THAL=thalamus; 
ACC=anterior cingulate cortex; OCC=occipital cortex (reference region)
P=.18                 P=.03     P=.14    P=.10                P=.07
MOR Binding Potential (BP) in Nicotine vs. Placebo Session
N=4 (2 sessions/subject)
BP
COMT as a novel therapeutic 
target for nicotine dependence
val
Nicotine-related Brain Reward Pathway
COMT
COMT val158met Polymorphism Predicts 
Smoking Relapse in Independent Studies













met/met   val/met    val/val met/met   val/met    val/val
Case-Control Study 
(n=785)
OR (relapse v. quit)
Prospective Clinical Trial   
(n=290)
OR (current v. former smoker)
P=0.03 P=0.03
COMT is a Potential Therapeutic Target
• Methylation enzyme involved in the inactivation 
of dopamine
• Common functional val158met variant (1 in 4 
are val/val)
• Val allele is associated with an increase in 
COMT activity and corresponding decrease in  
dopamine in frontal cortex
• Carriers of the val allele exhibit deficits in 
cognitive function
Hypothesis: Nicotine deprivation will produce cognitive deficits 
in smokers with val/val genotypes, an effect that may prompt 
smoking relapse to reverse deficits.
Imaging-Based Target Validation
Smokers scanned on two 
occasions (counterbalanced): (1) 
smoking as usual vs. (2) >14 hrs. 
abstinent (confirmed with CO)
Prospective genotyping
met/met: n=11   
val/met: n=12  
val/val: n=10
Genotype x abstinence effect (p=0.0005)
Loughead et al, Molecular Psychiatry, 2009
Dorsolateral prefrontal cortex
Brain Signature of Abstinence Effect on 
Cognitive Function in COMT val/val group
•Brain activation in smokers with val/val genotypes is reduced in 
abstinence during performance of difficult cognitive task
•Reduced activation is liked with slower performance in val/val 
group at higher task difficulty (p=0.03)
Tolcapone as a “Tool Compound” 
for Proof of Mechanism Study
• Inhibitor of COMT in central 
nervous system
• FDA-approved for the 
treatment of Parkinson’s 
Disease
• Cognitive enhancing effects












treatment with tolcapone 
200mg t.i.d. is safe and well 
tolerated by smokers
•Tolcapone (v. placebo) 
decreased speed of 
performance in val/val  
group at high task difficulty





Phase II Study of Tolcapone               
in Smokers
Medication run up Medication run up
Day 1 - 9 Day 28 - 37
Day 10 - 13 Day 38 - 41
Day 14 – 27 
WASH-OUT
3.5 days mandatory 
abstinence (CO 
confirmed)
3.5 days mandatory 
abstinence
PLACEBO/TOLCAPONE® TOLCAPONE®/PLACEBO
fMRI Scan fMRI Scan
Reversal of abstinence-induced cognitive deficits by 
tolcapone will provide “proof of mechanism”
Summary: COMT
Convergent genetic and pharmacologic evidence would support 
COMT as a therapeutic target for tobacco dependence 
COMT val allele is risk 
factor for nicotine 
dependence
Cognitive deficits are a core 
symptom of dependence and 
predict relapse
Smokers with val/val genotype  have altered 
brain function and cognitive deficits in 
abstinence
val

























Drug Development for Tobacco Dependence
Targeted Therapy for Tobacco Dependence
Nicotine Dependent Smokers Alter 





NICOTINE COTININE        3’Hydroxycotinine
CYP2A6                  CYP2A6
Active                            Inactive               Inactive
CYP2A6 Gene Mutations Alter 
Dependence Phenotypes
Genetically slow metabolizers 
smoke fewer cigs/day and are 
less dependent
CYP2A6 genotype alters 
enzyme activity and 
metabolite ratio
Malaiyandi et al., Molecular Psychiatry, 2006
Nicotine Metabolite Ratio Predicts                     
Therapeutic Response  to Nicotine Patch (n=480)
% Quit












1st Qrtl 2nd Qrtl 3rd Qrtl 4th Qtrl
Lerman et al., Clinical Pharmacology & Therapeutics,  2006
OR=.72 (.57-.91) p=006) •30% reduction in quit 
rates with increasing 
metabolic rate
•Reduction in plasma 
nicotine levels from 
patch
•Findings replicated
Is this specific to 
nicotine replacement 
therapy?
Patterson et al., Clinical Pharmacology & Therapeutics, 2008
% Quit 
Nicotine Metabolite Ratio Predicts                    

















1st Qrtl 2nd Qrtl 3rd Qrtl 4th Qrtl
Placebo
Bupropion
Slow                                                                    Fast
•Decreased quit 
rates also observed 
with placebo
•Increased liability 









Algorithm for Use of Nicotine Metabolite Ratio 
to Personalize Smoking Cessation Treatment












CYP2A6 gene linked 
with dependence 
phenotypes
Nicotine metabolite ratio is a 
stable measure of CYP2A6 
activity
Genetically slow metabolizers respond well to 
transdermal nicotine; fast metabolizers 
respond well to bupropion
Targeted therapy based on nicotine 
metabolite ratio is cost-effective
Evidence from prospective targeted 
therapy trial will support 
translation to practice
Test kit in development 
through industry 
collaboration
Summary and Implications  
•Genetics and neuroimaging 
provide powerful new tools for 
probing the biological basis of 
nicotine dependence
•A better understanding of biology 
will lead to better treatments and 
tests to personalize treatment to 
individual smokers 
•Reductions in tobacco use will 
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